PharmaSGP Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

PharmaSGP Holding hat ein Gesamteigenkapital von €44.7M und eine Gesamtverschuldung von €73.2M, wodurch sich der Verschuldungsgrad auf 163.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €140.9M bzw. €96.3M. PharmaSGP Holding Das EBIT des Unternehmens beträgt €26.3M, so dass der Zinsdeckungsgrad 7.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €46.3M.

Wichtige Informationen

212.5%

Verhältnis von Schulden zu Eigenkapital

€69.29m

Verschuldung

Zinsdeckungsgrad	8.2x
Bargeld	€40.40m
Eigenkapital	€32.61m
Gesamtverbindlichkeiten	€101.55m
Gesamtvermögen	€134.15m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PSGDie kurzfristigen Aktiva des Unternehmens (€73.9M) übersteigen seine kurzfristigen Passiva (€29.2M).

Langfristige Verbindlichkeiten: PSGDie kurzfristigen Vermögenswerte des Unternehmens (€73.9M) übersteigen seine langfristigen Verbindlichkeiten (€67.1M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PSGDie Nettoverschuldung im Verhältnis zum Eigenkapital (81.3%) wird als hoch angesehen.

Schulden abbauen: PSG hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Schuldendeckung: PSGDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (36.5%).

Zinsdeckung: PSGDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (7.4x Coverage) gut gedeckt.

PharmaSGP Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Second quarter 2024 earnings: EPS misses analyst expectations

PharmaSGP Holding SE to Report First Half, 2024 Results on Sep 26, 2024

Price target increased by 9.2% to €38.75

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen